As of 2024-12-14, the Relative Valuation of Vanda Pharmaceuticals Inc (VNDA) is (1.22) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.61 USD, the upside of Vanda Pharmaceuticals Inc based on Relative Valuation is -126.5%.
The range of the Relative Valuation is (2.93) - 2.87 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 24.1x | 15.2x |
| Forward P/E multiples | 19.0x - 31.4x | 20.2x |
| Fair Price | (2.93) - 2.87 | (1.22) |
| Upside | -163.6% - -37.8% | -126.5% |
| Date | P/E |
| 2024-12-12 | -16.44 |
| 2024-12-11 | -16.62 |
| 2024-12-10 | -16.37 |
| 2024-12-09 | -17.15 |
| 2024-12-06 | -17.22 |
| 2024-12-05 | -17.01 |
| 2024-12-04 | -17.22 |
| 2024-12-03 | -17.47 |
| 2024-12-02 | -17.93 |
| 2024-11-29 | -18.32 |
| 2024-11-27 | -18.47 |
| 2024-11-26 | -17.72 |
| 2024-11-25 | -17.97 |
| 2024-11-22 | -18.11 |
| 2024-11-21 | -17.58 |
| 2024-11-20 | -17.43 |
| 2024-11-19 | -17.51 |
| 2024-11-18 | -17.72 |
| 2024-11-15 | -17.79 |
| 2024-11-14 | -18.15 |
| 2024-11-13 | -19.43 |
| 2024-11-12 | -19.21 |
| 2024-11-11 | -19.00 |
| 2024-11-08 | -18.47 |
| 2024-11-07 | -17.86 |
| 2024-11-06 | -17.40 |
| 2024-11-05 | -17.04 |
| 2024-11-04 | -17.26 |
| 2024-11-01 | -16.58 |
| 2024-10-31 | -16.55 |
| 2024-10-30 | -16.22 |
| 2024-10-29 | -16.69 |
| 2024-10-28 | -17.01 |
| 2024-10-25 | -16.19 |
| 2024-10-24 | -16.08 |
| 2024-10-23 | -16.69 |
| 2024-10-22 | -16.83 |
| 2024-10-21 | -16.83 |
| 2024-10-18 | -17.47 |
| 2024-10-17 | -16.85 |
| 2024-10-16 | -17.43 |
| 2024-10-15 | -17.08 |
| 2024-10-14 | -17.11 |
| 2024-10-11 | -15.80 |
| 2024-10-10 | -15.69 |
| 2024-10-09 | -15.90 |
| 2024-10-08 | -15.98 |
| 2024-10-07 | -16.01 |
| 2024-10-04 | -16.47 |
| 2024-10-03 | -16.01 |